Multi-Agitator System for Mixing and Dispersion Requirements
Ross, Charles & Son’s VersaMix is a multi-shaft mixer designed for viscous applications requiring a high level of accuracy and batch-to-batch consistency.
Ross, Charles & Son’s VersaMix is a multi-shaft mixer designed for viscous applications requiring a high level of accuracy and batch-to-batch consistency. The mixer consists of two or three independently-driven agitators working in tandem to ensure high-speed fine dispersion, efficient turnover, and uniform heating/cooling.
The VMC-200 model has a maximum working capacity of 200 gallons. An air/oil lift raises and lowers the agitators into the vacuum-rated vessel. All product contact surfaces are stainless-steel type 316L polished 180-grit finish. The ASME 60-psi jacket on the vessel is insulated with two-inch thick mineral wool and sheathed with water-tight stainless-steel cladding.
Equipped with a 10HP anchor agitator, 20HP disperser, and 25HP rotor/stator, the mixer delivers a combination of laminar bulk flow and intensity necessary for homogenization and deagglomeration in high-viscosity conditions up to several hundred thousand centipoises. The vacuum cover includes multiple charging ports, viewing windows, tank light, and a thermoprobe. Finished product is discharged out of a three-inch pneumatically-actuated diaphragm valve installed on the tank’s conical bottom.
Available in standard sizes from 1- to 4000-gallon capacity, the mixer offers simple and reliable scalability from product development to full-scale production. Mixer features are tailored to a specific formulation or range of products for maximum functionality.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
